Page 3 - Dr. Lal Pathlabs

Stock picks by Sameet Chavan: Buy ITC, sell Dr Lal PathLabs

Dr Lal PathLabs' stock seems to have lost its sheen now as we are seeing consistent corrective moves over the past few weeks

Top trading ideas by Mehul Kothari of Anand Rathi: Buy HEG, L&T

HEG stock after trading with a strong uptrend recently underwent some consolidation

Near-term margin concerns and valuations weigh on Dr Lal Pathlabs

Some brokerages prefer Metropolis given higher realisation, revenue growth trajectory

Bet on these diagnostic stocks for up to 19% return as Covid-19 cases flare

According to the Union Health Ministry data, India recorded 1,03,558 coronavirus infections on Sunday, pushing the nationwide Covid tally to 1.25 crore

Dr Lal PathLabs hits record high in a weak market; surges 19% in 5 days

The company would continue to reap benefits from increased Covid-related and allied testing in its widespread network of diagnostic centers and labs, analysts believe

Sales recovery, expansion in new markets key to Dr Lal Pathlabs' growth

Higher competition, expansion may be a challenge for margin

Nifty outlook & trading strategies by CapitalVia: Buy SBI, Dr Lal PathLabs

Better-than-expected Q2 GDP data numbers might help index to move in the positive territory

Dr Lal PathLabs, Thyrocare slip on profit booking on Covid vaccine optimism

From March lows, the stock price of Thyrocare Technologies has been more-than-tripled and of Dr Lal PathLabs more-than-doubled on the BSE

Thyrocare, Dr Lal PathLabs: Healthcare stocks can rally more, charts show

A new all time high shows bullish sentiment is here to stay in these stocks.

Healthcare services stocks rally; Thyrocare up 35% in 2 days post Q2 update

Thyrocare Technologies, Metropolis Healthcare and Dr. Lal PathLabs, hitting their respective record highs, were up 9 per cent to 17 per cent on the BSE in intra-day trade.

Two pharma stocks that Ajit Mishra of Religare Broking is bullish on

All indicators point to a gradual rise in Aurobindo Pharma's stock from the 100 EMA support

Margin pressures likely to cap upside for Dr Lal Pathlabs: Analysts

The 29 per cent fall in volumes in the quarter was responsible for revenues declining 21 per cent year-on-year

Margin pressures to cap upside for Dr Lal Pathlabs as Covid dents volumes

Valuations too do not leave much scope for gains

Dr Lal PathLabs June quarter net profit declines 52% to Rs 28.4 crore

Diagnostic services provider Dr Lal PathLabs on Friday reported a 51.94 per cent decline in its consolidated net profit at Rs 28.4 crore for the quarter ended June 30, 2020.

Healthcare services stocks in focus; Dr Lal PathLabs, Thyrocare up over 5%

Metropolis Healthcare, meanwhile, rallied 7% to Rs 1,579 today, and were trading higher for the eighth straight day

Neuberg Diagnostics starts Covid-19 testing at its Chennai laboratory

Firm will be scaling up its capacity up to 2,000-2,500 tests a day as per ICMR norms by next week

Thyrocare Tech, Dr Lal Path Labs surge as pvt labs to conduct Covid-19 test

That apart, national laboratories have also been allowed to carry out clinical testing of Covid-19, as the number of cases went past 400 in India.

Kiran Mazumdar-Shaw wins EY Entrepreneur of the Year award for 2019

Awards announced for nine other categories; Adi Godrej gets Lifetime achievement award

Metropolis Healthcare leads diagnostics pack on higher realisation

Expansion, raising share of B2C network to help improve margins

Diagnostic players ride on changes in health insurance to beat slowdown

Metropolis, Dr Lal and Thyrocare are likely to see more gains led by expansion, increasing penetration, preventive testing and government's Ayushman Bharat scheme